NCNA

NuCana plc American Depositary Share Nasdaq Global Select
$2.95
Open: $2.72 High: $2.96 Low: $2.72 Close: $2.95
Range: 2021-06-23 - 2021-06-24
Volume: 567,495
Market: Open
Powered by Finage Stock APIDelayed data
NCNA
NuCana plc American Depositary Share 3 Lochside Way Edinburgh , EH12 9DT http://www.nucana.com
NuCana PLC is a clinical-stage biopharmaceutical company. It is focused on improving treatment outcomes for cancer patients by applying its ProTide technology.
  • CEO: Hugh Griffith
  • Employees: 20
  • Sector: Healthcare
  • Industry: Biotechnology
NCNA News
Latest news about the NCNA
  • NuCana to Present at the Jefferies Virtual Healthcare Conference

    EDINBURGH, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference being held from June 1 to June 4, 2021. Event: Jefferies Virtual Healthcare ConferenceDate: Tuesday, June 1, 2021Time: 9:30 AM ET The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com. About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors. Forward-Looking Statements This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. For more information, please contact: Hugh S. GriffithChief Executive OfficerNuCana plcTel: +44 131 357 1111info@nucana.com Westwicke, an ICR CompanyChris BrinzeyTel: +1 339-970-2843chris.brinzey@westwicke.com RooneyPartnersMarion JanicTel: +1 212-223-4017mjanic@rooneyco.com

    View More →
  • NuCana Reports First Quarter 2021 Financial Results and Provides Business Update

    Presented Encouraging Clinical Data at ASCO-GI and AACR Additional Clinical Data Announcements and Study Initiations Expected in 2021 EDINBURGH, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of March 31, 2021, NuCana had cash and cash equivalents of £78.6 million compared to £87.4 million as of December 31, 2020. NuCana continues to advance its various clinical programs and reported a net loss of £9.8 million for the quarter ended March 31, 2021, as compared to a loss of £4.0 million for the quarter ended March 31, 2020. Basic and diluted loss per share was £0.19 for the quarter ended March 31, 2021, as compared to £0.12 per share for quarter ended March 31, 2020. “We are very pleased with our momentum in 2021,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “In January, we presented data at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) from the NuTide:302 study demonstrating NUC-3373’s encouraging efficacy signals and favorable safety profile in patients with advanced colorectal cancer. Among the efficacy-evaluable population, a disease control rate of 62% was achieved. In addition, NUC-3373 was well tolerated with no hand-foot syndrome or neutropenia as well as lower rates of diarrhea, mucositis and stomatitis as compared to historical data for 5-FU and capecitabine in the frontline treatment of patients with colorectal cancer.” Mr. Griffith continued: “In April, we were excited to present five posters at the American Association for Cancer Research (AACR) Annual Meeting. NUC-3373 maintained the encouraging 62% disease control rate in the efficacy-evaluable population in the NuTide:302 study. The poster also detailed three patients who experienced reductions in their target lesions of 40%, 28% and 15% and several patients who achieved a longer progression-free survival on NUC-3373 than they had on their prior therapy. We also presented additional clinical data from the ongoing Phase I study of NUC-7738. These data demonstrated NUC-7738’s encouraging anti-cancer activity and favorable tolerability profile. Three case studies described patients who achieved tumor volume reductions and prolonged stable disease on NUC-7738. Other AACR posters showed NUC-3373-treated colon cancer cells are able to activate a natural killer cell response and described how NUC-7738 was designed to overcome the key cancer resistance mechanisms which have prevented the clinical development of its parent nucleoside analog, 3’-deoxyadenosine. Overall, these presentations highlighted the potential of our ProTides to significantly improve the treatment outcomes for patients with cancer.” Mr. Griffith concluded: “We are excited with the progress we have made so far in 2021. We remain focused on continuing to drive recruitment across all of our ongoing studies, including our Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer as well as initiating new studies, including our second Phase III study evaluating NUC-3373 in combination with other agents for patients with colorectal cancer. We look forward to providing additional updates as we go through 2021.” Anticipated 2021 Milestones Acelarin is a ProTide transformation of gemcitabine. In 2021, NuCana expects to: Complete recruitment sufficient to enable the first interim analysis in 2022 of the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-FU. In 2021, NuCana expects to: Report data from the Phase Ib study (NuTide:302) of NUC-3373 in combination with other agents with which 5-FU is typically combined, such as leucovorin, oxaliplatin and irinotecan in patients with advanced colorectal cancer;Initiate and report data from a Phase Ib expansion / Phase II study of NUC-3373 in combination with other agents for patients with colorectal cancer;Initiate a Phase III study of NUC-3373 in combination with other agents for patients with colorectal cancer; andReport data from the Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors. NUC-7738 is a ProTide transformation of a novel nucleoside analog, 3’-deoxyadenosine. In 2021, NuCana expects to: Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors; andInitiate a Phase II study of NUC-7738 in patients with solid tumors. About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors. Forward-Looking Statements This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. Unaudited Condensed Consolidated Statements of Operations For the Three Months EndedMarch 31, 2021 2020 (in thousands, except per share data) £ £Research and development expenses (8,706) (5,938)Administrative expenses (2,104) (1,609)Net foreign exchange (losses) gains (677) 2,127 Operating loss (11,487) (5,420)Finance income 24 144 Loss before tax (11,463) (5,276)Income tax credit 1,702 1,310 Loss for the period (9,761) (3,966) Basic and diluted loss per share (0.19) (0.12) Unaudited Condensed Consolidated Statements of Financial Position March 31, 2021 December 31, 2020 (in thousands) £ £Assets Non-current assets Intangible assets 4,764 4,753Property, plant and equipment 1,098 1,189Deferred tax asset 40 44 5,902 5,986Current assets Prepayments, accrued income and other receivables 4,813 4,628Current income tax receivable 11,529 9,822Cash and cash equivalents 78,625 87,356 94,967 101,806Total assets 100,869 107,792 Equity and liabilities Capital and reserves Share capital and share premium 143,135 142,937Other reserves 67,470 66,887Accumulated deficit (119,146) (110,594)Total equity attributable to equity holders of the Company 91,459 99,230 Non-current liabilities Provisions 46 46Lease liabilities 296 367 342 413 Current liabilities Trade payables 3,542 2,257Payroll taxes and social security 159 177Accrued expenditure 5,087 5,437Lease liabilities 280 278 9,068 8,149Total liabilities 9,410 8,562Total equity and liabilities 100,869 107,792 Unaudited Condensed Consolidated Statements of Cash Flows For the Three Months EndedMarch 31, 2021 2020 (in thousands) £ £Cash flows from operating activities Loss for the period (9,761) (3,966)Adjustments for: Income tax credit (1,702) (1,310)Amortization and depreciation 222 217Finance income (24) (144)Interest expense on lease liabilities 6 -Share-based payments 1,795 856Net foreign exchange losses (gains) 664 (2,164) (8,800) (6,511)Movements in working capital: (Increase) decrease in prepayments, accrued income and other receivables (191) 423Increase in trade payables 1,285 44Decrease in payroll taxes, social security and accrued expenditure (368) (165)Movements in working capital 726 302Cash used in operations (8,074) (6,209)Net income tax received - -Net cash used in operating activities (8,074) (6,209)Cash flows from investing activities Interest received 24 187Payments for property, plant and equipment (4) (10)Payments for intangible assets (138) (398)Net cash used in investing activities (118) (221)Cash flows from financing activities Payments for lease liabilities (74) (73)Proceeds from issue of share capital 198 -Net cash from (used in) financing activities 124 (73)Net decrease in cash and cash equivalents (8,068) (6,503)Cash and cash equivalents at beginning of period 87,356 51,962Effect of exchange rate changes on cash and cash equivalents (663) 2,141Cash and cash equivalents at end of period 78,625 47,600 For more information, please contact: NuCana plcHugh S. GriffithChief Executive Officer+44 131 357 1111info@nucana.com Westwicke, an ICR CompanyChris Brinzey+1 339-970-2843chris.brinzey@westwicke.com RooneyPartnersMarion Janic+1 212-223-4017mjanic@rooneyco.com

    View More →
  • Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

    View More →
  • NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit

    EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit being held virtually from May 4 to May 5, 2021. Event: 7th Annual Truist Securities Life Sciences SummitDate: May 4 to May 5, 2021 About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors. Forward-Looking Statements This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. For more information, please contact: Hugh S. GriffithChief Executive OfficerNuCana plcTel: +44 131 357 1111info@nucana.com Westwicke, an ICR CompanyChris BrinzeyTel: +1 339-970-2843chris.brinzey@westwicke.com RooneyPartnersMarion JanicTel: +1 212-223-4017mjanic@rooneyco.com

    View More →
  • NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

    NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer CellsNUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid TumorsNUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3’-dATPAcelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana’s ProTides in clinical development were presented. Summaries of the posters are described below.NUC-3373 NuCana presented two posters on NUC-3373, its ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU), a very widely used anti-cancer drug. NUC-3373 has been designed to overcome the main challenges associated with 5-FU and capecitabine, including cancer-resistance mechanisms, the generation of toxic metabolites and unfavorable pharmacokinetic profile. Poster Title: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer This poster describes further encouraging interim data from 38 patients with metastatic colorectal cancer. In this difficult-to-treat group, who had received a median of four prior lines of therapy, NUC-3373, with or without leucovorin, demonstrated a 62% disease control rate (defined as stable disease lasting more than 8 weeks) in the efficacy-evaluable population. Three patients experienced reductions in their target lesions of 40%, 28% and 15% and several patients achieved a longer progression-free survival on NUC-3373 than they had on their prior therapy. NUC-3373 also continues to demonstrate a favorable safety profile with no FBAL or FUTP-associated Grade 3 or 4 toxicities, such as hand-foot syndrome, GI or hematological adverse events. Poster Title: NUC-3373-induced DAMPs release in CRC cells promotes natural killer cell activation The second NUC-3373 poster showed that NUC-3373-treated colon cancer cells are able to activate a natural killer (NK) cell response. NUC-3373 was shown to induce the release of damage associated molecular patterns (DAMPs) which may restore NK cell-mediated immune responses by reducing inhibitory signals. Thus, NUC-3373 has the potential to evoke immunogenic cell death and may enhance the clinical utility of immunotherapy agents. NUC-7738 NuCana presented two posters on NUC-7738, a ProTide transformation of a novel nucleoside analog, 3’-deoxyadenosine or 3’-dA. NUC-7738, which has several potential anti-cancer mechanisms of action, is being evaluated in a Phase I study in patients with advanced solid tumors who have exhausted all standard therapies. Poster Title: NUC-7738, a novel ProTide transformation of 3’-deoxyadenosine, in patients with advanced solid tumors The first poster describes additional interim data from the ongoing Phase I study. These data demonstrate NUC-7738’s encouraging anti-cancer activity and favorable tolerability profile. Three case studies were described detailing patients who achieved tumor reductions and prolonged stable disease on NUC-7738. Poster Title: From bench to bedside: Using ProTide chemistry to transform 3’-deoxyadenosine into the novel anti-cancer agent NUC-7738 The second poster describes how NUC-7738 was designed to overcome the key cancer resistance mechanisms which have prevented the clinical development of 3’-dA. NUC-7738 was shown to efficiently generate high and prolonged intracellular levels of the active anti-cancer metabolite, 3’-dATP, and to cause cell death by activation of apoptotic pathways, as well as through inhibition of NFkB nuclear translocation. Acelarin Poster Title: NUC-1031 causes incorporation of fluorinated deoxycytidine into DNA, inducing persistent damage in biliary tract cancer cells NuCana presented a poster that further demonstrated Acelarin’s activity in biliary tract cancer cells. Specifically, the poster described how Acelarin (NUC-1031) is converted to the active anti-cancer metabolite (dFdCTP) and demonstrated that it is incorporated into DNA, inducing persistent double-strand breaks. This leads to cell cycle arrest and DNA damage resulting in apoptosis in biliary tract cancer cells. Abstracts and full session details can be found at www.aacr.org About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors. Forward-Looking Statements This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. For more information, please contact: NuCana plcHugh S. GriffithChief Executive OfficerT: +44 131 357 1111E: info@nucana.com Westwicke, an ICR CompanyChris BrinzeyT: +1 339-970-2843E: chris.brinzey@westwicke.com RooneyPartnersMarion JanicT: +1 212-223-4017E: mjanic@rooneyco.com

    View More →
  • NuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

    Presented Encouraging Clinical Data for NUC-3373 and NUC-7738 Continued to Enroll Global Phase III Biliary Tract Cancer Study (NuTide:121) of Acelarin with Potential for Accelerated Approval Filing Raised $80 million in a Follow-on Offering Augmented the Board of Directors with Two Key Appointments Numerous Clinical Data Announcements and Study Initiations Expected in 2021 EDINBURGH, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of December 31, 2020, NuCana had cash and cash equivalents of £87.4 million compared to £100.7 million at September 30, 2020 and £52.0 million at December 31, 2019. NuCana continues to advance its various clinical programs and reported a net loss of £12.3 million for the quarter ended December 31, 2020, as compared to £7.7 million for the quarter ended December 31, 2019. Net loss for the year ended December 31, 2020 was £30.7 million, compared to a net loss of £21.4 million for the year ended December 31, 2019. Basic and diluted loss per share was £0.24 for the quarter and £0.81 for the year ended December 31, 2020, as compared to £0.24 per share for the comparable quarter and £0.66 for the year ended December 31, 2019. “2020 was a very successful year for NuCana,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “Against the challenging backdrop of the COVID-19 pandemic, we continued to advance all of our clinical programs and generate encouraging clinical and non-clinical data. Throughout 2020, we made good progress in the Phase III NuTide:121 biliary tract cancer study and expect to enroll sufficient patients in 2021 to complete the first interim analysis in 2022, which may support an accelerated approval filing. In September, we provided an update on two of our lead programs at ESMO that further validate the use of our proprietary ProTide technology. NUC-3373 continued to demonstrate its potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen as compared to 5-FU in patients with colorectal cancer. We also announced the first-ever clinical data for NUC-7738, which showed promising indications of anti-cancer activity and a favorable tolerability profile.” Mr. Griffith continued: “During 2020, we completed a successful $80 million follow-on offering that significantly strengthens our balance sheet. We also appointed a new non-executive Chairman, Andrew Kay and a new non-executive director, Bali Muralidhar. Both individuals bring a wealth of experience and we look forward to their contributions as we advance NuCana’s programs.” Mr. Griffith concluded: “We were excited to begin 2021 with the announcement of additional interim data for NUC-3373 in patients with colorectal cancer that continued to demonstrate encouraging efficacy and safety at ASCO GI. We look forward to continuing to drive recruitment across all of our ongoing studies, announce additional clinical data, and initiate new studies in 2021. We remain focused on our mission of significantly improving treatment outcomes for patients with cancer.” Anticipated 2021 Milestones Acelarin is a ProTide transformation of gemcitabine. In 2021, NuCana expects to: Complete recruitment sufficient to enable the first interim analysis in 2022 of the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-FU. In 2021, NuCana expects to: Report data from the Phase Ib study (NuTide:302) of NUC-3373 in combination with other agents with which 5-FU is typically combined, such as leucovorin, oxaliplatin and irinotecan in patients with advanced colorectal cancer.Initiate and report data from a Phase Ib expansion / Phase II study of NUC-3373 in combination with other agents for patients with colorectal cancer.Initiate a Phase III study of NUC-3373 in combination with other agents for patients with colorectal cancer.Report data from the Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors. NUC-7738 is a ProTide transformation of a novel nucleoside analog, 3’-deoxyadenosine. In 2021, NuCana expects to: Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors.Initiate a Phase II study of NUC-7738 in patients with solid tumors. About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors. Forward-Looking Statements This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2020 to be filed with the Securities and Exchange Commission (“SEC”) on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. Condensed Consolidated Statements of Operations For the three months endedDecember 31, For the year endedDecember 31, 2020 2019 2020 2019 (in thousands, except per share data) (unaudited) £ £ £ £ Research and development expenses (7,981) (5,177) (25,899) (19,728)Administrative expenses (1,906) (1,722) (7,050) (5,953)Net foreign exchange losses (4,082) (2,210) (3,472) (1,019)Operating loss (13,969) (9,109) (36,421) (26,700)Finance income 12 182 246 1,049 Loss before tax (13,957) (8,927) (36,175) (25,651)Income tax credit 1,696 1,219 5,493 4,239 Loss for the period (12,261) (7,708) (30,682) (21,412) Basic and diluted loss per share (0.24) (0.24) (0.81) (0.66) Condensed Consolidated Statements of Financial Position at December 31, 2020 2019 (in thousands) £ £ Assets Non-current assets Intangible assets 4,753 3,960 Property, plant and equipment 1,189 1,109 Deferred tax asset 44 46 5,986 5,115 Current assets Prepayments, accrued income and other receivables 4,628 4,710 Current income tax receivable 9,822 8,481 Cash and cash equivalents 87,356 51,962 101,806 65,153 Total assets 107,792 70,268 Equity and liabilities Capital and reserves Share capital and share premium 142,937 80,840 Other reserves 66,887 62,737 Accumulated deficit (110,594) (80,055)Total equity attributable to equity holders of the Company 99,230 63,522 Non-current liabilities Provisions 46 26 Lease liabilities 367 538 413 564 Current liabilities Trade payables 2,257 2,412 Payroll taxes and social security 177 160 Accrued expenditure 5,437 3,342 Lease liabilities 278 268 8,149 6,182 Total liabilities 8,562 6,746 Total equity and liabilities 107,792 70,268 Condensed Consolidated Statements of Cash Flowsfor the year ended December 31, 2020 2019 (in thousands) £ £ Cash flows from operating activities Loss for the year (30,682) (21,412)Adjustments for: Income tax credit (5,493) (4,239)Amortization and depreciation 890 718 Finance income (246) (1,049)Interest expense on lease liabilities 26 - Share-based payments 4,305 3,226 Net foreign exchange losses 3,481 1,006 (27,719) (21,750)Movements in working capital: Increase in prepayments accrued income and other receivables (9) (2,452)Decrease in trade payables (155) (43)Increase in payroll taxes, social security and accrued expenditure 2,112 393 Movements in working capital 1,948 (2,102) Cash used in operations (25,771) (23,852)Net income tax received 4,152 19 Net cash used in operating activities (21,619) (23,833)Cash flows from investing activities Interest received 319 1,116 Payments for property, plant and equipment (361) (46)Payments for intangible assets (1,271) (1,215)Net cash used in investing activities (1,313) (145)Cash flows from financing activities Payments of lease liabilities (297) (197)Proceeds from lease incentives received - 25 Proceeds from issue of share capital – exercise of share options 15 125 Proceeds from issue of share capital 66,581 - Share issue expenses (4,499) - Net cash from (used in) financing activities 61,800 (47)Net increase (decrease) in cash and cash equivalents 38,868 (24,025)Cash and cash equivalents at beginning of year 51,962 76,972 Effect of exchange rate changes on cash and cash equivalents (3,474) (985)Cash and cash equivalents at end of year 87,356 51,962 For more information, please contact: NuCana plcHugh S. GriffithChief Executive OfficerT: +44 131 357 1111E: info@nucana.com Westwicke, an ICR CompanyChris BrinzeyT: +1 339-970-2843E: chris.brinzey@westwicke.com RooneyPartnersMarion JanicT: +1 212-223-4017E: mjanic@rooneyco.com

    View More →
  • NuCana to Participate in Three Upcoming Investor Conferences

    EDINBURGH, United Kingdom, Feb. 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in the following conferences: Cowen 41st Annual Health Care ConferencePresentation Date: Thursday, March 4, 2021Presentation Time: 1:30 PM ET H.C. Wainwright Global Life Sciences Conference Dates: March 9-10, 2021 Oppenheimer's 31st Annual Healthcare Conference Presentation Date: Thursday, March 18, 2021Presentation Time: 9:20 AM ET The presentations at the Cowen 41st Annual Health Care Conference and Oppenheimer's 31st Annual Healthcare Conference will be webcast live. Both presentations will be available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com. About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors. Forward-Looking Statements This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. For more information, please contact: Hugh S. GriffithChief Executive OfficerNuCana plcTel: +44 131 357 1111info@nucana.com Westwicke, an ICR CompanyChris BrinzeyTel: +1 339-970-2843chris.brinzey@westwicke.com RooneyPartnersMarion JanicTel: +1 212-223-4017mjanic@rooneyco.com

    View More →
  • What Is The Ownership Structure Like For NuCana plc (NASDAQ:NCNA)?

    Every investor in NuCana plc ( NASDAQ:NCNA ) should be aware of the most powerful shareholder groups. Generally...

    View More →
  • NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

    Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy Safety Profile Continues to be FavorableEDINBURGH, United Kingdom, Jan. 15, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.NuTide:302 is a three-part study investigating NUC-3373, NuCana’s targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer. The study is evaluating NUC-3373’s optimal dose and schedule in combination with agents commonly used to treat patients with colorectal cancer and is assessing safety, pharmacokinetics and anti-cancer activity. NUC-3373 has been designed to overcome the main challenges associated with 5-FU and capecitabine, including cancer-resistance mechanisms which limit efficacy, off-target toxicity and administration burdens.The ASCO GI presentation highlighted data from 37 patients treated in Part I of the study who received NUC-3373 either as monotherapy or in combination with leucovorin. Ten patient case studies highlighted NUC-3373’s ability to stabilize disease and achieve prolonged durations of progression-free survival. Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of therapy and five patients experienced tumor shrinkage. These patients included: * A fourth-line patient who achieved a Partial Response with a 40% reduction in tumor volume; * A third-line patient who achieved a 28% reduction in tumor volume after their disease rapidly progressed through all prior fluoropyrimidine-containing regimens.Among the efficacy-evaluable population, a disease control rate of 62% was achieved.In addition to these encouraging efficacy signals, the presentation compared the safety profile of NUC-3373 in Part I of the study with historical data for 5-FU and capecitabine in the front-line treatment of patients with colorectal cancer. NUC-3373 was well tolerated with no hand-foot-syndrome or neutropenia as well as lower rates of diarrhea, mucositis and stomatitis.Dr. Andrew Coveler, Associate Professor at the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center and an investigator in the NuTide:302 study, remarked: “I am encouraged by both the clinical activity and safety of NUC-3373. To observe this anti-cancer activity, including a Partial Response, in such a heavily pre-treated patient population is very promising. In addition, NUC-3373 has been well tolerated and its safety appears favorable when compared to 5-FU and capecitabine. As such, I look forward to advancing NUC-3373’s development in patients with colorectal cancer.”“We are very pleased with these additional data from Part I of the NuTide:302 study,” said Hugh S. Griffith, NuCana’s Founder and CEO. “It was particularly encouraging to observe tumor shrinkages, prolonged disease stabilization and a favorable safety profile in a patient population that had received at least two prior fluoropyrimidine-containing regimens. We look forward to continuing Part II of the study in which NUC-3373 is being combined with leucovorin and either oxaliplatin or irinotecan. Our objective is to replace 5-FU and capecitabine with NUC-3373 as the backbone of treatment for patients with colorectal cancer.”Details of the poster presentation are as follows: Title: A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302)  Session: Colorectal Cancer Abstract Number: 93 About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.Forward-Looking StatementsThis press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.For more information, please contact:NuCana plc Hugh S. Griffith Chief Executive Officer T: +44 131 357 1111 E: info@nucana.comWestwicke, an ICR Company Chris Brinzey T: +1 339-970-2843 E: chris.brinzey@westwicke.comRooneyPartners Marion Janic T: +1 212-223-4017 E: mjanic@rooneyco.com

    View More →
  • These 2 Penny Stocks Could Surge Over 300%, Say Analysts

    Risk and reward often travel hand-in-hand, making the stock market both lucrative and dangerous. Among the best exemplars of this axiom are the penny stocks, those equities priced at $5 or less. With that low price comes the potential for extreme gains, as even an incrementally small price increase will translate to a high percentage gain.JPMorgan's Head of Small and Midcap Equity Strategy, Eduardo Lecubarri, sees both the opportunities and dangers in the current market environment – and the great potential of small-cap stocks that have room to run.“1Q may be rocky following the strong gains since Nov and the fact that valuations are sitting on all-time highs. However, the year long outlook is encouraging due to far more powerful fundamental tailwinds. Such a positive backdrop is likely to keep investors chasing those few stocks that still offer big recovery upside, as they seem to have started to do YTD. It is for this reason that we would encourage investors to build their portfolios now and see things through in the event of any consolidation phase that may come in Q1,” Lecubarri wrote.Taking the risk into consideration, we used TipRanks’ database to find compelling penny stocks with bargain price tags. The platform steered us towards two tickers sporting “Strong Buy” consensus ratings from the analyst community. Not to mention substantial upside potential is on the table. We are talking returns of at least 300% over the next 12 months, according to the analysts.AcelRx Pharmaceuticals (ACRX)Opioids have made headlines in recent years, and for all the wrong reasons. These potent pain relief drugs are also dangerously addictive – a factor that has led to the opioid epidemic in the US. AcelRx is a pharmaceutical company dedicated to the creation of safer treatments for acute pain, developing synthetic opioid drugs for sublingual (under the tongue) dosing.The company’s main product, Sufentanil, was approved by the FDA under the name Dsuvia in 2018, and by the EU as Dzuveo that same year. A second sublingual Sufentanil system, under the name Zalviso, has also been approved for use by the EU, and is in Phase 3 trial in the US.In its most recent earning report, the company showed $1.4 million at the top line, driven by $1.3 million in product sales. The sales figure was up 433% sequentially, and the total revenue figure was up 133% year-over-year.Against this backdrop, several members of the Street believe ACRX’s $1.40 share price looks like a steal.Cantor analyst Brandon Folkes is upbeat on Dsuvia’s prospects as an alternative to current opioid treatments, and he believes that potential will boost the company’s stock.“With the launch of Dsuvia, we believe investor focus can now shift to launch metrics and peak sales potential for the product. As ACRX launches a true alternative to IV opioids, we expect investors to begin to appreciate the value of the product. We believe that Dsuvia offers an advancement in delivery of adequate pain treatment by eliminating the need for an invasive and time-consuming IV set-up in the emergency room, as well as an outpatient, or post-surgery, setting. Despite hospital launches taking time, we expect the uptake of Dsuvia to drive revenue upside beyond the Street's current estimates, which, in turn, could drive the stock higher from current levels,” Follked opined.In line with his bullish stance, Folkes rates ACRX a Buy, and his $9 price target implies room for a stunning 552% upside potential in the next 12 months. (To watch Folkes’ track record, click here)Turning now to the rest of the Street, 3 Buys and no Holds or Sells have been published in the last three months. Therefore, ACRX has a Strong Buy consensus rating. Based on the $7 average price target, shares could soar 407% in the next year. (See ACRX stock analysis on TipRanks)NuCana (NCNA)NuCana is a biopharma company focused on new cancer treatments. The company’s goal is to provide effective treatments for biliary, breast, colorectal, ovarian, and pancreatic cancers – while avoiding the complications and side effects of current chemotherapy treatments. NuCana uses a phosphoramidate chemistry technology called ProTide to create a class of drugs that will surmount the limitations of the existing nucleotide analogs behind many chemotherapy drugs. NuCana’s ProTides have already been used in Gilead’s antiviral drug Sovaldi.In May of last year, NuCana announced the restart of its Phase III trial on Acelarin, the drug candidate furthest along the company’s pipeline, as a treatment for biliary tract cancers. The study encompasses over 800 patients in 6 countries and is currently ongoing. In November, the company published data described as ‘encouraging’ from the Phase Ib study of the same drug.While Acelarin is the flagship drug in the pipeline, NuCana has two other prospects under development. NUC-3373 is in Phase I trial as a treatment for solid tumors and colorectal cancers, and NUC-7738 is a second pathway under investigation for applications to advanced solid tumors. Of these three, the colorectal study is the farthest advanced.Writing from Truist, 5-star analyst Robyn Karnauskas sees the pipeline as key to NuCana’s investor potential.“We believe investors have overlooked the fact that NCNA is a platform Company that we believe is validated, as defined by the production of clinical products. We like that it has brought 3 products to the clinic, including one novel drug and two improved cornerstone chemos. The data suggest to us that the platform works and can produce better chemos […] While investors are mostly focused on Acelarin, we believe investors should also focus on NUC-3373, another core to our platform-based thesis that has data expected in 1H2021,” Karnauskas noted.To this end, Karnauskas puts a $22 price target on NCNA, suggesting the stock has room for 384% growth ahead of it, along with a Buy rating. (To watch Karnauskas’ track record, click here)Overall, NCNA's Strong Buy consensus rating is unanimous, and based on 4 recent reviews. Shares have an average price target of $17.33, suggesting a 270% one-year upside from the current trading price of $4.69. (See NCNA stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

    View More →
  • NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session

    NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

    View More →
  • NuCana Appoints Andrew Kay as Board Chairman

    Pharmaceutical Executive Brings a Wealth of Experience to NuCana’s Board of Directors Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy TherapeuticsEDINBURGH, United Kingdom, Dec. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Andrew Kay as Chairman of its Board of Directors.“We are delighted to welcome Andrew as NuCana’s Board Chairman,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “Andrew is an internationally recognized executive and brings a wealth of leadership experience at several successful biotechnology and pharmaceutical companies. His track record of building shareholder value throughout his career, along with his experience taking compounds through development and commercialization will bring significant value to NuCana. We look forward to working with Andrew as we advance our ProTide pipeline.”Andrew Kay said, “I look forward to serving as Chairman of NuCana’s Board as we leverage our ProTide technology platform with the aim of developing more efficacious and better tolerated medicines for patients with cancer. With several important ongoing clinical studies and numerous upcoming data announcements, I believe this is an exciting time to be joining NuCana’s Board.”Andrew Kay brings more than 30 years of experience in building and leading biotechnology and pharmaceutical companies. Andrew currently serves as Chairman of the Board of NeRRe Therapeutics and Blueberry Therapeutics. He also recently held the same role for KaNDy Therapeutics, a biotechnology company that was acquired by Bayer for a deal value of up to $875 million in 2020, and for Wilson Therapeutics, a biopharmaceutical company acquired by Alexion Pharmaceuticals for $855 million in 2018. Prior to that, Andrew served as the President and Chief Executive Officer for Algeta. During Andrew’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration-resistant prostate cancer patients, followed by a strong commercial launch. In February 2014, Algeta was acquired by Bayer AG for $2.9 billion. Prior to Algeta, Andrew was the Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and held several other senior commercial positions in Europe and the US having worked at AstraZeneca, Eli Lilly, Sandoz and Boots.About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical studies, including a Phase III study for patients with advanced biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.Forward-Looking StatementsThis press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.For more information, please contact:NuCana plc Hugh S. Griffith Chief Executive Officer T: +44 131 357 1111 E: info@nucana.comWestwicke, an ICR Company Chris Brinzey T: +1 339-970-2843 E: chris.brinzey@westwicke.comRooneyPartners Marion Janic T: +1 212-223-4017 E: mjanic@rooneyco.com

    View More →
  • Is NCNA A Good Stock To Buy Now?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

    View More →
  • The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 30) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) * argenx SE - ADR (NASDAQ: ARGX) * Beam Therapeutics Inc (NASDAQ: BEAM) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BioLife Solutions Inc (NASDAQ: BLFS) * BioNTech SE - ADR (NASDAQ: BNTX) (reacted to reports of imminent approval for its coronavirus vaccine candidate in the U.K.) * BioTelemetry Inc (NASDAQ: BEAT) * Blueprint Medicines Corp (NASDAQ: BPMC) * BridgeBio Pharma Inc (NASDAQ: BBIO) * Cardiff Oncology Inc (NASDAQ: CRDF) * Cellectis SA (NASDAQ: CLLS) * Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) * Chimerix Inc (NASDAQ: CMRX) * China Biologic Products Holdings Inc (NASDAQ: CBPO) * Crispr Therapeutics AG (NASDAQ: CRSP) * CureVac BV (NASDAQ: CVAC) (announced third-quarter results and plans to initiate Phase 2b/3 study of its coronavirus vaccine candidate) * Eidos Therapeutics Inc (NASDAQ: EIDX) * Fate Therapeutics Inc (NASDAQ: FATE) * Foghorn Therapeutics Inc. (NASDAQ: FHTX) * Generation Bio Co (NASDAQ: GBIO) * Inhibrx Inc (NASDAQ: INBX) * Inspire Medical Systems Inc (NYSE: INSP) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Mersana Therapeutics Inc (NASDAQ: MRSN) (announced the appointment of a new chief medical officer) * Moderna Inc (NASDAQ: MRNA) (announced positive efficacy and safety data from Phase 3 study of coronavirus vaccine candidate and filing for emergency use authorization) * Myovant Sciences Ltd (NYSE: MYOV) * NeoGenomics, Inc. (NASDAQ: NEO) * Neuronetics Inc (NASDAQ: STIM) * Nurix Therapeutics Inc (NASDAQ: NRIX) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Oncorus Inc (NASDAQ: ONCR) * Praxis Precision Medicines Inc (NASDAQ: PRAX) * Pulmonx Corp (NASDAQ: LUNG) * Spero Therapeutics Inc (NASDAQ: SPRO) * Stoke Therapeutics Inc (NASDAQ: STOK) * Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Trillium Therapeutics Inc (NASDAQ: TRIL) * Trinity Biotech plc (NASDAQ: TRIB) * Veracyte Inc (NASDAQ: VCYT) * Zai Lab Ltd - ADR (NASDAQ: ZLAB)None of the NYSE or Nasdaq-listed biopharma stocks and medical device manufacturers hit fresh 52-week highs Nov. 30.Stocks In Focus Amarin Accuses Hikma Of Infringing Vascepa Patents Amarin Corporation plc (NASDAQ: AMRN) said it has filed a patent infringement lawsuit against Hikma Pharma and Hikma's U.S. affiliate, alleging Hikma has infringed on certain patents related to its Vascepa by selling and importing icosapent ethyl capsules in or into the U.S.The lawsuit was filed in the U.S. District Court in Delaware."The Amarin complaint details its position that Hikma has knowingly and willfully introduced its generic product in a manner that infringes Amarin's patent rights and has exceeded the scope of permitted Hikma activity," Amarin said.Amarin shares were up 4.44% at $5.18 premarket Tuesday. Pfizer, BioNTech Files Marketing Authorization Application For Coronavirus Vaccine Candidate In Europe Pfizer Inc. (NYSE: PFE) and its partner BioNTech announced the submission Monday of a formal application for Conditional Marketing Authorization to the European Medicines Agency for BNT162b2, the companies' investigational vaccine against SARS-CoV-2.The companies said the submission completes the rolling review process initiated on Oct. 6.In premarket trading Tuesday, Pfizer shares were rising 2.27% to $39.18 and BioNTech shares were down 0.88% at $123.15. MacroGenics Strikes Commercialization Partnership For Cancer Drug Ahead of Approval MacroGenics Inc (NASDAQ: MGNX) said it has partnered with Eversana, a commercial services company to the global life sciences industry, to commercialize margetuximab in the U.S. if it is approved.Maegetuximab has a PDUFA action date of Dec. 16, by which time the FDA will decide whether to approve the monoclonal antibody for the treatment of breast cancer.Under the agreement, Eversana stands to receive a co-exclusive right to conduct approved commercialization activities for which it will be compensated with the right to earn future revenue share payments that are capped at 125% of Eversana's cumulative service fees, MacroGenics said.Entera Bio Appoints Biopharma Industry Veteran As CEO Entera Bio Ltd (NASDAQ: ENTX) said its board has appointed Spiros Jamas to the role of CEO and as a member of the board effective Jan. 4, 2021. Jamas will succeed Dr. Roger Garceau, who has been serving as interim CEO since August. "Spiros Jamas is a biotech entrepreneur with over 30 years of senior management experience in the biopharmaceutical industry," Entera Bio said.The stock was up 1.62% to $1.25 in after-hours trading.Related Link: The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions NuCana's Chemo Combo Found More Effective Than Standard-Of-Care In Early Stage Study NuCana PLC (NASDAQ: NCNA) announced publication in the online edition of The Oncologist final results of the Phase 1b study of Acelarin plus cisplatin for patients with advanced biliary tract cancer, confirming a high objective response rate and favorable safety profile.The ORR for the Acelarin plus cisplatin was 44% compared to the 26% ORR for Eli Lilly And Co's (NYSE: LLY) gemcitabine plus cisplatin."We are very encouraged by the final efficacy and safety data from ABC-08", said Hugh Griffith, NuCana's CEO."We are committed to developing Acelarin plus cisplatin as the first approved front-line treatment for patients with advanced biliary tract cancer."The stock gained 12.06% to $5.11 in after-hours trading.Galapagos Reports Positive Proof-Of-Concept Topline Data For Idiopathic Pulmonary Fibrosis Drug Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) announced positive topline results for its investigational GPR84 antagonist GLPG1205 in a proof-of-concept Phase 2 trial in idiopathic pulmonary fibrosis patients.The company said it plans to advance the investigational asset into a dose-finding Phase 2b study.Boston Scientific To Divest BTG Specialty Pharma Business For $800M In Cash Boston Scientific Corporation (NYSE: BSX) said it has entered into a definitive agreement with SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash.SERB, backed by private equity firm Charterhouse Capital Partners, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases, Boston Scientific said.The transaction is expected to close in the first half of 2021, subject to customary regulatory approvals and other closing conditions.Offerings Intellia Therapeutics Inc (NASDAQ: NTLA) said it has commenced an underwritten public offering of $150 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Intellia.The stock slid 3.23% at $38 premarket Tuesday. Cogent Biosciences Inc (NASDAQ: COGT) said it has commenced an underwritten public offering of $60 million in shares of its common stock. All the shares are being sold by the company.The stock was down 13.35% premarket at $8.50.On The Radar PDUFA Dates The FDA will decide on Vanda Pharmaceuticals Inc.'s (NASDAQ: VNDA) sNDA for Hetlioz capsules and its NDA for the liquid formulation of Hetlioz for the treatment of adults and children, respectively, with Smith-Magenis Syndrome.Related Link: Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions * Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist

    Acelarin plus Cisplatin’s High Objective Response Rate and Favorable Safety Profile ConfirmedNuTide:121 Global Phase III Study Recruitment OngoingEDINBURGH, United Kingdom, Nov. 30, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the final results of the Phase Ib study of Acelarin plus cisplatin for patients with advanced biliary tract cancer (ABC-08) have been published online ahead of print in The Oncologist. Encouraging interim data had previously been reported and the final data confirm the high objective response rate and favorable safety profile of Acelarin plus cisplatin in this patient population.In the efficacy-evaluable patient population, the Objective Response Rate was 44%. By comparison, in the ABC-02 study, which led to gemcitabine plus cisplatin becoming the current standard of care for the first-line treatment of patients with advanced biliary tract cancer, an Objective Response Rate of 26% was achieved in the efficacy-evaluable population.Dr. Mairéad McNamara, Co-Chief Investigator of the ABC-08 study and Senior Lecturer and Honorary Consultant in Medical Oncology at the University of Manchester and The Christie NHS Foundation Trust remarked: “Acelarin combined with cisplatin demonstrated a favorable safety profile and achieved good tumor control. Responses were seen across all five biliary tract cancer sub-types, including a Complete Response in one patient, a very rare occurrence in this patient population. In ABC-02, only one out of 161 efficacy-evaluable patients who received gemcitabine plus cisplatin achieved a Complete Response. Additionally, one patient with Stable Disease, whose tumor had initially been considered unsuitable for surgical resection, was able to have complete surgical removal of the tumor following treatment with Acelarin plus cisplatin. Four patients were still alive at the end of follow-up, having survived between 16 and 36 months.”“We are very encouraged by the final efficacy and safety data from ABC-08“, said Hugh S. Griffith, NuCana’s founder and CEO. “We are committed to developing Acelarin plus cisplatin as the first approved front-line treatment for patients with advanced biliary tract cancer. We continue to drive recruitment in the ongoing Phase III NuTide:121 Study where we believe we have the potential opportunity to apply for accelerated approval based on Objective Response Rate. We remain on track to enroll the required number of patients in NuTide:121 by the end of 2021 in order to conduct the first interim analysis in 2022.”Professor Juan Valle, Co-Chief Investigator of the ABC-02, ABC-08 and NuTide:121 studies and Professor and Honorary Consultant in Medical Oncology at the University of Manchester and The Christie NHS Foundation Trust said: “Biliary tract cancer is a devastating disease for which more effective treatments are desperately needed. While targeted therapies and immunotherapies may play a role in the treatment of biliary tract cancer in the future, chemotherapy will remain the backbone of treatment. Medicines like Acelarin, with the potential for improved efficacy and safety, would be welcome additions to the treatment options for patients with biliary tract cancer.”About NuTide:121 NuTide:121 is a global, multi-center, randomized Phase III study that is enrolling up to 828 patients in approximately 130 sites across North America, Europe, Asia and Australia. Patients are being randomized 1:1 and treated with either a combination of Acelarin (725 mg/m2) plus cisplatin (25 mg/m2) or the current standard of care regimen, gemcitabine (1,000 mg/m2) plus cisplatin (25 mg/m2). The primary objectives of NuTide:121 are Overall Survival (OS) and Objective Response Rate (ORR). Three interim analyses, including two designed to support accelerated approval, are planned as part of the Phase III study protocol, in addition to the final analysis. Based on discussions with the FDA and subject to any further regulatory guidance, the Company believes that a statistically significant improvement in ORR at either of the first two interim analyses, supported by positive trends in other endpoints, could potentially allow for an accelerated approval of a new drug application (NDA) for Acelarin. Accelerated approval requires a confirmatory clinical study to verify the drug’s clinical benefit. If accelerated approval were to occur, NuTide:121 would continue and the Company anticipates that data from subsequent analyses could provide the confirmatory data to support full (regular) approval.About Biliary Tract Cancer Biliary tract cancer, including cholangiocarcinoma, gallbladder and ampullary carcinoma, is cancer originating in the bile duct, a vessel that transports bile from the liver to the gallbladder and small intestine. Approximately 178,000 new cases of biliary tract cancer are diagnosed each year worldwide, with more than 18,000 of those diagnoses in the United States. There are currently no agents approved for the treatment of biliary tract cancer; however, the worldwide standard of care in the first-line setting for patients with advanced biliary tract cancer is the combination of gemcitabine and cisplatin.About NuCana plc NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical studies, including a Phase III study for patients with advanced biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.Forward-Looking Statements This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the potential for accelerated approval of Acelarin; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. For more information, please contact:Hugh S. Griffith Chief Executive Officer NuCana plc Tel: +44 131 357 1111 info@nucana.comWestwicke, an ICR Company Chris Brinzey Tel: +1 339-970-2843 chris.brinzey@westwicke.comRooneyPartners Marion Janic Tel: +1 212-223-4017 mjanic@rooneyco.com

    View More →
  • NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update

    Completed Successful $80 million Public Offering Presented Encouraging Data for NUC-3373 and NUC-7738 at the ESMO Virtual Congress 2020EDINBURGH, United Kingdom, Nov. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.As of September 30, 2020, NuCana had cash and cash equivalents of £100.7 million compared to £47.8 million at June 30, 2020 and £52.0 million at December 31, 2019. This cash balance includes the net proceeds from NuCana’s public offering in September 2020. NuCana continues to advance its various clinical programs and reported a net loss of £8.4 million for the quarter ended September 30, 2020, as compared to £3.9 million for the quarter ended September 30, 2019. Basic and diluted loss per share was £0.24 for the quarter as compared to £0.12 per share for the prior-year quarter.“We are very pleased with our achievements during the third quarter,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “We significantly augmented our financial position with the successful completion of this public offering, supporting our progress towards several important milestones. These milestones include filing a New Drug Application (“NDA”) for Acelarin in biliary tract cancer, filing an NDA for NUC-3373 in colorectal cancer, and completing a Phase II clinical study for NUC-7738, in each case subject to regulatory feedback and clinical outcomes.”Mr. Griffith continued: “We also presented encouraging data at the ESMO Virtual Congress 2020, including a poster highlighting interim data from the ongoing Phase Ib study of NUC-3373 in combination with other agents typically combined with 5-FU in patients with advanced colorectal cancer (NuTide:302) and a poster detailing the first-ever clinical data from the ongoing Phase I study of NUC-7738 in patients with advanced solid tumors (NuTide:701). We believe the data from the NuTide:302 study support the potential of NUC-3373 to improve progression-free survival in patients who had relapsed or were refractory to prior 5-FU-containing regimens. We also believe these data show NUC-3373’s potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen as compared to 5-FU. With respect to NUC-7738, we believe the interim data from the NuTide:701 study demonstrate that NUC-7738 has a favorable pharmacokinetic and tolerability profile and is showing encouraging anti-cancer activity.”Mr. Griffith concluded, “We continue to drive recruitment in all of our ongoing studies and remain focused on our mission of developing safer and more effective medicines for patients with cancer.”Anticipated 2021 Milestones * Acelarin is a ProTide transformation of gemcitabine. In 2021, NuCana expects to: °  Complete recruitment to enable the first interim analysis of the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer. * NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-FU. In 2021, NuCana expects to: °  Report data from the Phase Ib study (NuTide:302) of NUC-3373 in combination with other agents with which 5-FU is typically combined, such as leucovorin, oxaliplatin and irinotecan in patients with advanced colorectal cancer. °  Initiate and report data from a Phase Ib expansion / Phase II study of NUC-3373 in combination with other agents for patients with colorectal cancer. °  Initiate a Phase III study of NUC-3373 in combination with other agents for patients with colorectal cancer. °  Report data from the ongoing Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors. * NUC-7738 is a ProTide transformation of a novel nucleoside analog, 3’-deoxyadenosine. In 2021, NuCana expects to: °  Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors. °  Initiate a Phase II study of NUC-7738 in patients with solid tumors.About NuCana plcNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.Forward-Looking StatementsThis press release may contain “forward‐looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the sufficiency of the Company’s current cash and cash equivalents; the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the fact that the Company’s expectations as to the sufficiency of the Company’s current cash and cash equivalents to fund its planned operations excludes any potential costs related to pre-commercial activities or, if approved, commercialization costs, as well as the risks and uncertainties set forth in the "Risk Factors" section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. Unaudited Condensed Consolidated Statements of Operations        For the three months ended September 30,  For the nine months ended September 30,    2020 2019  2020 2019   (in thousands, except per share data)  £ £  £ £             Research and development expenses(6,117)(4,845) (17,918)(14,551) Administrative expenses(1,906)(1,423) (5,144)(4,231) Net foreign exchange (losses) gains(1,601)1,227  610 1,191  Operating loss(9,624)(5,041) (22,452)(17,591) Finance income26 252  234 867  Loss before tax (9,598)(4,789) (22,218)(16,724) Income tax credit1,204 912  3,797 3,020  Loss for the period(8,394)(3,877) (18,421)(13,704)                       Basic and diluted loss per share(0.24)(0.12) (0.55)(0.42)        Unaudited Condensed Consolidated Statements of Financial Position September 30, 2020 December 31, 2019   (in thousands)  £ £  Assets   Non-current assets   Intangible assets4,686 3,960  Property, plant and equipment1,281 1,109  Deferred tax asset34 46   6,001 5,115  Current assets   Prepayments, accrued income and other receivables5,065 4,710  Current income tax receivable8,140 8,481  Cash and cash equivalents100,678 51,962   113,883 65,153  Total assets119,884 70,268  Equity and liabilities   Capital and reserves   Share capital and share premium142,937 80,840  Other reserves65,740 62,737  Accumulated deficit(98,403)(80,055) Total equity attributable to equity holders of the Company110,274 63,522      Non-current liabilities   Provisions46 26  Lease liabilities441 538   487 564      Current liabilities   Trade payables4,190 2,412  Payroll taxes and social security138 160  Lease liabilities278 268  Accrued expenditure4,517 3,342   9,123 6,182      Total liabilities9,610 6,746      Total equity and liabilities119,884 70,268        Unaudited Condensed Consolidated Statements of Cash Flows For the nine months ended September 30,  2020 2019   (in thousands)  £ £  Cash flows from operating activities   Loss for the period(18,421)(13,704) Adjustments for:   Income tax credit(3,797)(3,020) Amortization and depreciation667 522  Finance income(234)(867) Interest expense on lease liabilities20 -  Share-based payments3,069 2,191  Net foreign exchange gains(619)(1,228)  (19,315)(16,106) Movements in working capital:   Increase in prepayments, accrued income and other receivables(408)(3,593) Increase (decrease) in trade payables1,778 (300) Increase in payroll taxes, social security and accrued expenditure1,153 8  Movements in working capital2,523 (3,885) Cash used in operations(16,792)(19,991) Net income tax received4,152 20  Net cash used in operating activities(12,640)(19,971) Cash flows from investing activities   Interest received300 915  Payments for property, plant and equipment(350)(29) Payments for intangible assets(1,079)(988) Net cash used in investing activities(1,129)(102) Cash flows from financing activities   Payments of lease liabilities(223)(146) Proceeds from issue of share capital – exercise of share options15 117  Proceeds from issue of share capital66,581 -  Share issue expenses(4,499)-  Net cash from (used in) financing activities 61,874 (29) Net increase (decrease) in cash and cash equivalents48,105 (20,102) Cash and cash equivalents at beginning of period51,962 76,972  Effect of exchange rate changes on cash and cash equivalents611 1,221  Cash and cash equivalents at end of period100,678 58,091        For more information, please contact:NuCana plc Hugh S. Griffith Chief Executive Officer T: +44 131 357 1111 E: info@nucana.comWestwicke, an ICR Company Chris Brinzey T: +1 339-970-2843 E: chris.brinzey@westwicke.comRooneyPartners Marion Janic T: +1 212-223-4017 E: mjanic@rooneyco.com

    View More →
  • NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020. Event: Piper Sandler 32nd Annual Healthcare Conference Pre-Recorded Presentation Replay: November 23, 2020 – December 3, 2020The presentation will be pre-recorded and available for replay starting Monday, November 23, 2020 at 10:00 AM ET under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com.About NuCana plcNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.Forward-Looking StatementsThis press release may contain “forward‐looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.For more information, please contact:Hugh S. Griffith Chief Executive Officer NuCana plc Tel: +44 131 357 1111 info@nucana.comWestwicke, an ICR Company Chris Brinzey Tel: +1 339-970-2843 chris.brinzey@westwicke.comRooneyPartners Marion Janic Tel: +1 212-223-4017 mjanic@rooneyco.com

    View More →
  • NuCana to Present at the Jefferies Virtual London Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual London Healthcare Conference. Event: Jefferies Virtual London Healthcare Conference Presentation Date: Wednesday, November 18, 2020 Presentation Time: 11:45 AM GMTThe presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com.About NuCana plcNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.Forward-Looking StatementsThis press release may contain “forward‐looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.For more information, please contact:Hugh S. Griffith Chief Executive Officer NuCana plc Tel: +44 131 357 1111 info@nucana.comWestwicke, an ICR Company Chris Brinzey Tel: +1 339-970-2843 chris.brinzey@westwicke.comRooneyPartners Marion Janic Tel: +1 212-223-4017 mjanic@rooneyco.com

    View More →
  • Why NuCana (NCNA) Might Surprise This Earnings Season

    NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    View More →
  • NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar

    Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public OfferingEDINBURGH, United Kingdom, Oct. 13, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Bali Muralidhar, M.D., Ph.D. to its Board of Directors. “We are delighted to welcome Bali to NuCana’s Board,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “He is internationally recognized for his investing acumen in the life sciences sector and we believe his financial and clinical experience will bring significant value to NuCana as we advance our ProTide pipeline. We believe Abingworth’s decision to make a substantial investment in NuCana as part of our recent successful public offering further validates the potential of our ProTides to transform the treatment of patients with cancer. We were pleased that we were able to attract several new specialist healthcare investors to this financing in addition to the significant support from our existing investors. This financing will enable NuCana to advance the development of our ProTides and achieve several important milestones.”Dr. Muralidhar said, “We are excited to be a substantial new investor in NuCana. I look forward to serving on the NuCana Board as they leverage their ProTide technology platform to develop more efficacious and safer medicines for patients with cancer.”About AbingworthAbingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams and building world-class companies. Since 1973, Abingworth has invested in 167 life science companies, leading to more than 40 M&A/exits and close to 70 IPOs. Abingworth’s therapeutic focused investments fall into 3 categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California) and Boston.About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.Forward-Looking StatementsThis press release may contain “forward‐looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.For more information, please contact:NuCana plc Hugh S. Griffith Chief Executive Officer T: +44 131 357 1111 E: info@nucana.comWestwicke, an ICR Company Chris Brinzey T: +1 339-970-2843 E: chris.brinzey@westwicke.comRooneyPartners Marion Janic T: +1 212-223-4017 E: mjanic@rooneyco.com

    View More →